Skip to content
Study details
Enrolling now

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University
NCT IDNCT07101445ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

94

Study length

about 1.3 years

Ages

18+

Locations

1 site in GA

What this study is about

This trial is testing whether a premedication regimen with methylprednisolone or dexamethasone helps prevent allergic reactions to motixafortide in patients with multiple myeloma undergoing stem cell mobilization. The goal is to determine which medication, methylprednisolone or dexamethasone, is better at preventing these reactions.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Electronic Health Record Review
  • 2.Questionnaire Administration
  • 3.Receive Recombinant Granulocyte Colony-Stimulating Factor
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

paracetamol (Reduces fever and pain (mechanism not fully understood)), dexamethasone, famotidine, loratadine, methylprednisolone, montelukast (Leukotriene receptor antagonist; reduces inflammation in airways), motixafortide, colony stimulating factor

Drug routes

oral, injection, ocular, oral (Oral Tablet), oral (Disintegrating Oral Tablet), injection (Injection), subcutaneous

Endpoints

Secondary: Compare Tolerability Between Regimens, Cytokine levels

Procedures

diagnostic

Body systems

Oncology